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Relationship between sensitivity to dyspnea 
and fluctuating peak expiratory flow rate in the 
absence of asthma symptoms
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Background: Exacerbation of asthma has a negative impact on quality of life and increases the risk of fatal asthma. One of the known 
risk factors for patients with a history of near-fatal asthma is reduced sensitivity to dyspnea.
Objective: We aimed to identify patients with such risk before they experienced severe exacerbation of asthma.
Methods: We analyzed asthma symptoms and peak expiratory flow rate (PEFR) values of 53 patients recorded daily in a diary over 
a mean period of 274 days. Patients matched their symptoms to one of eight categories ranging in severity from ‘absent’ to ‘severe 
attack’. We then analyzed the relationship between PEFR and asthma symptoms by dividing the PEFR value by the values of clinical 
parameters, including asthma symptom level.
Results: Average PEFR was 75.2% (50.5-100%) in the ‘absent’ symptom category, 64.5% (36.6-92.6%) in ‘wheeze’, 57.3% (25.0-94.7%) 
in ‘mild attack’ and 43.6% (20.4-83.1%) in ‘moderate attack’, with the personal best reading taken as 100%. Thus, differences in PEFR in 
patients in the same symptom category varied widely. PEFR in wheeze, mild attack and moderate attack did not correlate significantly 
with duration of asthma, forced expiratory volume in one second or proportion of personal best to standard predicted PEFR values. 
These PEFRs showed no significant difference in groups divided by type of regular treatment, but showed a significant negative 
correlation with the coefficient of variation (CV) of PEFR when asthma symptoms were absent. CV for absent symptoms should be 
between +4.0 and −4.0% when using regression analysis to measure PEFR if the decreased PEFR is in agreement with guidelines.
Conclusion: To determine which patients have reduced sensitivity to dyspnea, CV of PEFR should be considered when asthma 
symptoms are reported as absent. When patients present with more than 8% fluctuation in PEFR, we should intervene in their 
treatment, even when they claim to be stable.
Key words: Asthma; Asthma exacerbation; Peak expiratory flow; Severity
Correspondence: Kumiya Sugiyama
Department of Pulmonary Medicine and Clinical 
Immunology, Dokkyo Medical University, Mibu, Tochigi 
321-0293, Japan
Tel: +81-282-87-2151
Fax: +81-282-86-5080
E-mail: sugiyama@dokkyomed.ac.jp
Received: August 25, 2011
Accepted: January 4, 2012
This is an Open Access article distributed under the terms of the Creative 
Commons Attribution. Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is 
properly cited.
Copyright © 2012. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. 
http://apallergy.orgapallergy.org
kamiya k, et al. 
Asia Pacific
allergy
http://dx.doi.org/10.5415/apallergy.2012.2.1.49 50
IntRoduCtIon
The Wright peak flow meter was introduced in 1958, but 
clinicians at that time did not recognize its value for the 
management of asthma [1]. Later, reports appeared which showed 
good correlation between peak expiratory flow rate (PEFR) and 
forced expiratory volume in one second (FEV1) [2-5] as well as 
good outcome when PEFR was utilized for the management 
of asthma [6-10]. Following the publication of recommended 
guidelines for asthma by the National Institutes of Health and 
the Japanese Society of Allergology [11-13], in which a moderate 
attack is defined as a PEFR between 60% and 80% of the personal 
best, PEFR monitoring has become popular in Japan because it is 
easily performed and is fairly accurate.
PEFR monitoring by keeping an asthma diary has two important 
uses. First, physicians can easily determine the level of asthma 
control since the patient’s last visit because they can compare 
the new PEFR with that recorded in the asthma diary at the time 
of the previous visit. The diary also allows physicians to manage 
asthma objectively without patient input, which avoids insufficient 
treatment of asthma based on patients misperceiving and thus 
misreporting the severity of their asthma. Second, in relation to 
patients themselves, it is useful for those patients who do not 
always perceive their asthma symptoms accurately, especially 
those who misperceive their symptoms to be mild instead of more 
serious airway obstruction. This reduced sensitivity to dyspnea is 
known to be one of the risk factors of fatal asthma in patients with 
a history of near-fatal asthma [14-19]. Therefore, PEFR monitoring is 
useful for both patients and doctors.
By keeping an asthma diary, patients learn to perceive their 
asthma symptoms more accurately. This will ultimately assist them 
in evaluating their asthma symptoms more accurately without the 
need to check their PEFR. However, simply keeping a diary cannot 
improve asthma, because PEFR monitoring alone is unlikely to 
improve mortality [20]. Our impression is that patients who have 
frequent asthma attacks often misinterpret their symptoms as 
being mild, when in fact they may have serious airway obstruction. 
Therefore, it is important that patients with exacerbations of 
asthma analyze their asthma diaries in relation to PEFR monitoring 
so that they can understand the association between PEFR and 
their symptoms. 
The aim of this study was to identify patients with reduced 
sensitivity to dyspnea before they experience severe exacerbation 
of asthma and require medical intervention. To identify these 
patients, we compared PEFRs recorded in the asthma diary with 
other clinical data. 
MEtERIALS And MEthodS
Study design
We prospectively enrolled patients with asthma who recorded 
both asthma symptoms and PEFRs on a daily basis for an average 
period of 274 days. Then, the relationship between PEFRs and 
symptoms noted in the diaries was retrospectively analyzed. If the 
asthma diary included at least one record of an attack of dyspnea 
or wheezing in the previous month, the physician explained the 
purpose of the study to the prospective subject. If the patient 
consented to participate, he/she was enrolled and the physician 
was provided all of the asthma diaries kept by the patient (Fig. 
1). Pulmonary diffusing capacity was measured and a chest X-ray 
taken to exclude patients with chronic obstructive pulmonary 
disease. The study protocol was approved by the ethics committee 
of Dokkyo Medical University (No 23059).
Subjects
Fifty-three patients were enrolled in the study (Table 1). Forty-
two patients regularly used inhaled corticosteroids (<400 µg/day 
of beclomethasone (BDP), n = 10; 400 µg/day of BDP, n = 17; >400 
µg/day of BDP, n = 15), 33 regularly used oral corticosteroids, and 
31 regularly used both. Asthma diaries, which were provided by 
these subjects, included data that covered periods ranging from 
21 to 832 days. The mean duration of recording asthma data was 
274 days. 
Analysis and statistics
Patients noted their asthma symptoms in the diary twice a 
day (morning and evening) before self-administering asthma 
drugs such as theophylline, beta2-adrenergic agonists, and 
corticosteroids [22, 23]. They classified their symptoms according 
to the criteria of the Japanese Society of Allergology as one of 
eight categories ranging in severity from ‘absent’ to ‘severe attack’ 
(Table 2). Subjects also measured PEFR twice a day (morning and 
evening) by using a peak flow meter before self-administering 
asthma drugs and noted the PEFR value in their asthma diary. 
The best PEFR for the duration of analysis was defined as the 
“personal best PEFR”. There are three models of peak flow meters 
commercially available in Japan. Although we did not designate apallergy.org
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one specific model for study use, patients were asked to use the 
same peak flow meter throughout their observation period. 
The average PEFR and standard deviation (SD) for each symptom 
category were calculated for each patient. Data are expressed as 
mean ± SD (minimum–maximum). To evaluate the variation of 
PEFR, the coefficient of variation (CV) was used. CV is calculated as 
SD/mean × 100 (%) and is useful for comparing variation between 
mean values [24]. Because mean PEFR is different between patents, 
CV is best for evaluating the variation of PEFR. CV of the PEFR for 
each symptom category was calculated for each patient. 
We defined patients as having reduced sensitivity to dyspnea 
when they experienced a moderate attack with a PEFR of <60%. 
This is based on the definition of a moderate attack a PEFR 
between 60% and 80% of the personal best [25, 26]. When 
patients present asthma attacks, the sensitivity to dyspnea will be 
normal, if the decreased PEFR agrees with the above guideline. 
But, although the PEFR is decreased widely, if the patient feels as 
mild symptom, it will be insensitive for dyspnea.
Pulmonary function was calculated using the following 
parameters: forced vital capacity (FVC), FEV1, flow rate at 50% of 
FVC (V
4
50) and flow rate at 25% of FVC (V
4
25). FVC, V
4
50, and V
4
25 were 
evaluated as a percentage of the predicted standard values [27, 
28].
RESuLtS
PefR according to symptom categories
The average PEFR was 43.6 ± 18.8% (20.4-83.1%) for ‘moderate 
attack’, 57.3 ± 18.2% (25.0-94.7%) for ‘mild attack’, 64.5 ± 13.5% 
(36.6-92.6%) for ‘wheeze’, 65.8 ± 15.8% (31.1-93.6%) for ‘shortness 
of breath (SOB)’, 55.8 ± 16.2% (32.5-79.2%) for ‘severe cough’, 
67.5 ± 11.7% (31.1-93.6%) for ‘mild cough’, and 75.2 ± 11.1% (50.5-
100%) for ‘absent’, with the personal best reading taken as 100% 
(Table 1). None of the patients experienced a severe attack during 
the observation period, although 24 patients presented <60% of 
personal best PEFR, which is classified as a severe attack according 
to the guidelines [25, 26]. Decreases in the PEFR varied widely in 
patients who experienced a moderate attack (20.4-83.1%), and 
some patients reported only mild symptoms despite having a very 
low PEFR.
Asthma
patients
without
COPD
Yes
No
Excluded
Keep
asthma
diary with
PEFR
Either
wheezing
or severe
in the
previous
month
Consent
to
participate
Yes
No
Excluded
Yes
No
Excluded
Yes
No
Excluded
Enrolled
fig. 1. Flow chart for enrollment. COPD, chronic obstructive pulmonary disease; PEFR, peak expiratory flow rate.
Table 1. Baseline clinical characteristics
Characteristic Mean ± SD
   Age (years) 49.6 ± 16.3
   Sex (M/F) 28/25
   Duration of asthma (years) 14.0 ± 8.9
   Atopic/Non-atopic 35/18
   Pulmonary function
     FVC (% of predicted) 95.4 ± 20.8
     FEV1 (%) 65.1 ± 14.1
     V
4
50 (% of predicted) 35.0 ± 24.2
     V
4
25 (% of predicted) 26.9 ± 19.2
   Severity of asthma
*
     Step 1 0
     Step 2 0
     Step 3 9
     Step 4 11
     Step 5 33
   Duration of observation (days) 273.8 ± 210.8
FVC, forced vital capacity; FEV1, forced expiratory volume in one second; V
4
50, 
flow rate at 50% of FVC; V
4
25, flow rate at 25% of FVC. 
*GINA 2010 [21].apallergy.org
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Sensitivity to dyspnea
Average PEFR for each patient who had experienced a moderate 
attack (n = 13), mild attack (n = 33) or wheeze (n = 52) was used to 
determine their sensitivity to dyspnea. Patients with lower PEFRs 
in each symptom category were evaluated for insensitivity to 
dyspnea. 
First, PEFR was compared between patients divided into three 
groups according to type of regular asthma treatment: oral 
corticosteroids, inhaled corticosteroids including asthma drugs but 
without oral corticosteroids, and other treatments without inhaled 
or oral corticosteroids. No significant differences were observed 
between the groups (Fig. 2). Next, the correlation between average 
PEFR for each symptom severity category and pulmonary function 
was analyzed (Fig. 3). A significant correlation between PEFR and 
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fig. 2. For each patient, the average value of peak expiratory flow rate (PEFR) was calculated for moderate attack, mild attack, and wheeze, in relation 
to personal best as 100%. Patients were divided into groups according to their regular treatment. The relationship between PEFR and regular treatment 
showed no significant relationship with reduced sensitivity to dyspnea for any of the symptoms of moderate attack, mild attack or wheeze. Data are 
expressed as mean ± SD. ICS, inhaled corticosteroid; N.S., not significant.
Table 2. Categories of asthma exacerbation [13]
 
Symptom category Degree of breathlessness Mean PEFR (% of personal best)
Severe attack
Dyspnea: too severe to move
Speech: difficult
Daily living: impossible
not available
Moderate attack
Dyspnea: orthopnea
Speech: moderately difficult
Daily living: difficult
43.6 ± 18.8 (n = 13)
Mild attack
Dyspnea: but able to assume supine position
Speech: almost normal
Daily living: slightly difficult
57.3 ± 18.2 (n = 33)
Wheeze
No dyspnea at rest; wheeze only
Speech: normal
Daily living: almost normal
64.5 ± 13.5 (n = 52)
Shortness of breath
Dyspnea on rapid movement
Speech: normal
Daily living: normal
65.8 ± 15.8 (n = 33)
Severe cough Severe cough without dyspnea 55.8 ± 16.2 (n =  8)
Mild cough Mild cough without dyspnea 67.5 ± 11.7 (n = 43)
Absent No dyspnea on rapid movement 75.0 ± 11.1 (n = 52)
PEFR, peak expiratory flow rate.apallergy.org
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fig. 3. For each patient, the average value of peak expiratory flow rate (PEFR) was calculated for moderate attack, mild attack, and wheeze, in relation 
to personal best as 100%. Correlations between PEFR and pulmonary function were analyzed for each symptom. A significant correlation was seen only 
for % flow rate at 25% of FVC (V
4
25) in the case of mild attack and wheeze. PEFR for each symptom, which is stipulated by the aforementioned guidelines, 
is shown as a gray line. FVC, forced vital capacity; FEV1, forced expiratory volume in one second.
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fig. 4. For each patient, the average value of peak expiratory flow rate (PEFR) was calculated for moderate attack, mild attack, and wheeze, in relation 
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with PEFR. However, the coefficient of variation (CV) of PEFR when asthma symptoms were reported to be absent showed a significant negative corre-
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%V
4
25 was observed for mild attack and wheeze. Moreover, average 
PEFR showed a significant negative correlation with CV for the 
absent symptom category (Fig. 4), but no significant correlation 
with the proportion of personal best to standard PEFR or the 
duration of asthma for any of the three symptom categories. 
The standard PEFR was obtained from a table of PEFR values for 
normal, healthy Japanese subjects [29].
Improvement of perception of dyspnea
Sensitivity to dyspnea was improved in some patients after their 
asthma was totally controlled over the course of the study, as a 
result of recording their symptoms and monitoring PEFR on a daily 
basis. The example of a 39-year-old female patient is shown in Fig. 
5. PEFR was decreased to 30.6% in the first moderate attack, with 
an average PEFR of 77.3% and CV of 11% in the preceding month 
when asthma symptoms were recorded as being absent. When 
PEFR decreased to around 60%, she understood her symptoms 
to be SOB, and not moderate attack. However, when the patient 
experienced the next moderate attack after 3 months, PEFR had 
decreased to a lesser extent (67.3%), with a better average PEFR 
of 84.5% and CV of 6% in the preceding month when asthma 
symptoms were recorded as being absent. If she had experienced 
the same attack 3 months earlier, she might have interpreted the 
attack as SOB. The reason that she was able to understand her 
symptoms correctly was that her sensitivity to dyspnea had been 
improved. Thus, after asthma is totally controlled, sensitivity to 
dyspnea will improve.
What is the optimum CV value in asthma patients experienc-
ing no symptoms?
In a moderate attack, PEFR should be between 60% and 80% 
of the personal best, and in a mild attack or wheeze, it should 
be greater than 80% of the personal best, as stipulated by the 
aforementioned guidelines [25, 26]. The regression lines in Fig. 4C 
show PEFR in a moderate attack (85.222 – 2.86466 × CV), mild 
attack (90.002 – 2.36989 × CV) and wheeze (86.617 – 1.67059 × 
CV). If the PEFR stipulated by the guidelines is ideal, then the CV for 
a moderate attack should be between 1.8% and 8.8%, and the CV 
for a mild attack and wheeze should be less than 4.2% and 4.0%, 
respectively. The variation in PEFR, when patients perceive their 
symptoms accurately according to the aforementioned guidelines, 
should be in agreement with the above three conditions, with a 
CV of 1.8-4.0%. CV should always be less than 4.0%. In the present 
study, CV, which is calculated by dividing SD by the mean, was 
used to avoid differences of mean PEFR values. Therefore, variation 
should be evaluated as ±CV instead of ±SD. On the basis of the 
above calculations, the variability of PEFR in the absence of asthma 
symptoms should be less than ±4.0%, and the range of variation 
should be <8.0% of the personal best. This suggests that, if the 
personal best PEFR value is 500, then the variability of PEFR while 
experiencing no symptoms should stay below 40.
dISCuSSIon
It has been reported that patients with a history of near-fatal 
asthma show reduced sensitivity to dyspnea [14-19]. In other 
words, these patients incorrectly perceive their symptoms to be 
mild rather than to be a more serious case of airway obstruction, 
and as such they can experience a severe attack without 
premonitory symptoms. It is important, therefore, to determine 
which patients are at risk before they experience a severe attack. 
However, because it is not easy to test the sensitivity to dyspnea in 
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fig. 5. Peak expiratory flow rate (PEFR) monitoring for a 39-year-old 
female patient as an example case. PEFR was decreased to 30.6% in first 
moderate attack, and average PEFR and coefficient of variation (CV) in 
the reported absence of asthma symptoms for 1 month before the attack 
were 77.3% and 0.11, respectively (A). However, when the patient present-
ed the next moderate attack 3 months after her asthma was fully con-
trolled after episode A, PEFR was much less decreased to 67.3%, which 
the patient presented as shortness of breath (SOB) in episode A. Average 
PEFR and CV in the absence of asthma for the preceding 1 month were 
also better at 84.5% and 0.06, respectively (B). Thus, reduced sensitivity to 
dyspnea was improved. 
A bapallergy.org
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every patient, we chose to analyze the PEFRs recorded in asthma 
diaries. 
The majority of patients in our hospital with asthma are treated 
according to the guidelines and their condition is well controlled. 
In the present study, therefore, only 53 patients were enrolled. 
Furthermore, more than half of the patients were severe, because 
only those who presented with an attack of dyspnea or wheezing 
in the previous month were enrolled. The relationship between 
exacerbation of asthma and PEFR was analyzed, and the severity of 
asthma did have an effect on our study. We examined 13 patients 
with moderate attack, 33 with mild attack and 52 with wheeze 
over a long observation period, which was sufficient for analyzing 
factors to determine the risk of severe attack. Although we 
examined no patients with severe attack, 24 patients presented 
with <60% of the personal best PEFR, and those exacerbations 
should be regarded as severe attacks. In addition, it proved 
effective to evaluate the difference in PEFR for the same symptom 
category between patients. To analyze the insensitivity to dyspnea, 
we consider these subjects were useful in our study.
Before we analyzed the data, we expected that patients with 
reduced sensitivity to dyspnea would be categorized as having 
severe asthma because, in our clinical experience, asthma attacks 
are more prevalent in patients with severe asthma than mild 
asthma. However, the severity value divided by the treatment 
value did not show a significant relation to reduced sensitivity, and 
some patients showed normal sensitivity to dyspnea even when 
fully treated (including those treated with oral corticosteroids). 
Taking multiple drugs including oral corticosteroids is not a direct 
risk factor for reduced sensitivity to dyspnea in itself, but it is 
important that asthma is completely absent.
Airway remodeling is indicated by chronic and irreversible 
airway obstruction [30] and causes airway hyper-responsiveness, 
and recurrence of airway inflammation occurs readily [31]. Airway 
remodeling is a known risk factor for fatal asthma [32], and small 
airways are major sites of remodeling in fatal asthma [33]. V
4
25 is an 
indicator of airway obstruction in small airways and is not easily 
improved by treatment. In the present study, significant correlation 
was seen between %V
4
25 and PEFR in mild attack and wheeze. For 
moderate attack, a significant correlation is probable if a higher 
number of subjects are studied. Thus, airway remodeling may 
contribute to reduced sensitivity to dyspnea.
It has been reported that fluctuation in PEFR is related to airway 
hyper-responsiveness and is one of the risk factors for fatal asthma 
[34, 35]. It would be useful if airway hyper-responsiveness could 
be reliably predicted by the variation in PEFR without examination. 
This was the reason behind analyzing the relationship between CV 
of PEFR in the reported absence of asthma symptoms and initial 
airway hyper-responsiveness. However, no significant correlation 
was found (data not shown), because our results were based on a 
long period of observation. In Fig. 5A, a wide fluctuation of PEFR is 
expected to indicate an increase in airway hyper-responsiveness. 
On the other hand, a narrow fluctuation of PEFR is expected 
to indicate a decrease in airway hyper-responsiveness Fig. 5B. 
Because airway hyper-responsiveness is improved by treatment, 
the relationship between initial airway hyper-responsiveness and 
fluctuation in PEFR on a long period of observation cannot be 
established.
CV is suitable for evaluating the fluctuation in PEFR because 
differences in age, height and sex between patients are not 
confounding factors. When asthma symptoms are reportedly 
absent, patients’ PEFRs should approximately match their personal 
best, and CV will be almost zero. However, patients with poorly 
controlled asthma showed fluctuations in PEFR in the reported 
absence of asthma symptoms. Although CV in this situation is 
a useful measure, it has two disadvantages. First, patients can 
become tired of calculating it on every occasion. Second, it is 
unclear why variation is better for totally controlled asthma. To 
resolve these problems, using the regression analysis data shown 
in Fig. 4C, we calculated PEFR variability for those patients who 
reported an absence of symptoms. The results showed that 
the PEFR variability in such patients needs to be below 8% to 
achieve the established relationship between PEFR and asthma 
symptoms according to the guidelines [25, 26]. Whether SD of ± 
1 is an appropriate range for the variability is debatable; however, 
to accord with the guidelines, it is advisable to keep the PEFR 
variability of a patient who reports an absence of symptoms below 
8%. 
It is important to evaluate fluctuations in PEFR in the reported 
absence of asthma symptoms in patients without a family doctor, 
as suggested by Sugiyama et al [36]. They reported that patients 
who visited an emergency room with exacerbation of asthma 
could be roughly divided into two groups. One group comprised 
patients with severe asthma who were generally older: these 
patients often experience exacerbation of asthma despite being 
treated at hospital regularly. The other group comprised patients 
without a family doctor: although these patients believe their 
asthma to be mild, some of them have more than mild asthma. 
Asthma specialists do not always have the chance to evaluate apallergy.org
Fluctuating PEFR reduces sensitivity of dyspnea
http://dx.doi.org/10.5415/apallergy.2012.2.1.49 57
patients’ asthma because they visit emergency rooms only for 
exacerbation of the condition. If they are given a peak flow meter 
to take home in the emergency room, and if it is explained that a 
fluctuating or low PEFR value is not mild asthma, this may decrease 
the number of patients at risk of fatal asthma.
In conclusion, asthma diaries with PEFRs recorded contain 
important information. A peak flow meter is cheap and easy for 
patients to use and can easily be introduced into the patient’s 
treatment by a physician who is not an asthma specialist. To 
ascertain which patients have reduced sensitivity to dyspnea, the 
most important factor to consider is the CV of PEFR when patients 
report an absence of asthma symptoms. When such patients 
present with fluctuating PEFR values, we should intervene in their 
treatment even when they claim to be stable.
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